Randomised trial of hyperimmune immunoglobulin in hospitalised COVID-19: pre-therapy Fc receptor binding SARS-CoV-2 antibody associated with better outcomes.
BACKGROUND: Neutralising monoclonal antibodies prevent and treat COVID-19 if administered early after infection with sensitive SARS-CoV-2 variants. Despite containing high neutralising antibodies, hyperimmune intravenous immunoglobulin (hIVIG) generally fails to mitigate severe COVID-19. We probed potential reasons for this discrepancy in a recent large, randomised trial (NCT04546581). METHODS: Multiplex bead arrays were used to measure SARS-CoV-2 specific FcγR binding and neutralising activity in pre-treatment sera from 481 subjects (231 placebo vs. 250 hIVIG). Associations between pre-therapy antibody FcγR engagement and day 7 clinical outcome were evaluated. RESULTS: Elevated levels of FcγRIIIa engagement by baseline spike (S)-specific antibody were associated with better clinical outcomes in COVID-19 hospitalised patients across both hIVIG- and placebo-treated groups (OR=0.43, 95%CI 0.30-0.63). Higher nucleocapsid (N) antibody-mediated FcγR engagement and surrogate neutralisation in pre-treatment sera were also modestly associated with improved outcomes. Higher pre-therapy S-specific FcγR binding antibody was also associated with reduced SARS-CoV-2 viral loads. CONCLUSIONS: Higher pre-therapy S-specific FcγR binding antibody, but not additional FcγR binding antibody provided by hIVIG, was associated with improved outcomes in severe COVID-19. Pre-existing FcγR engaging antibody, along with rapid production of these antibodies in placebo-treated subjects, may dilute potential benefits from hIVIG therapy. This work helps guide development of more strategic, targeted treatment of severe SARS-CoV-2 infection with antibody-based therapeutics.
Authors
- Sarah Lilian Pett (ORCID: https://orcid.org/0000-0002-4851-4727)
- Kevin John Selva (ORCID: https://orcid.org/0000-0002-0780-9422)
- Jens‐Ulrik Stæhr Jensen (ORCID: https://orcid.org/0000-0003-4036-0521)
- Stephen John Kent (ORCID: https://orcid.org/0000-0002-8539-4891)
- Hillary A. Vanderven (ORCID: https://orcid.org/0000-0001-8482-2308)
- Mark Niccolo Polizzotto (ORCID: https://orcid.org/0000-0002-6446-183X)
- Cavan Reilly (ORCID: https://orcid.org/0000-0002-6695-9113)
- Anthony Dominic Kelleher (ORCID: https://orcid.org/0000-0002-0009-3337)
- Amy W. Chung (ORCID: https://orcid.org/0000-0003-0020-9704)
- Win Min Han (ORCID: https://orcid.org/0000-0003-3731-7960)
- Sean Liu
- Zaiyah Habib
Institutions
- Australian National University (AU)
- University of Copenhagen (DK)
- University of Minnesota (US)
- The University of Melbourne (AU)
- Australian Institute of Tropical Health and Medicine (AU)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- UNSW Sydney (AU)
- MRC Clinical Trials Unit at UCL (GB)
- Peter Doherty Institute (AU)
- Institute of Human Virology (NG)
- Kirby Institute (AU)
- University College London (GB)
- James Cook University (AU)
- Medical Research Council (GB)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1093/infdis/jiag561
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00